Horizon Discovery, which started operations in 2007, is one of the fastest growing biotechnology companies in Europe by Deloitte with a staff of more than 80 people spread across scientific, operations and commercial functions and accommodated within a 17,800 sq. ft. state-of-art facility in Cambridge, UK.
Horizon has been built upon a 20 year heritage in oncology research, translational medicine and gene-editing. This background is the basis of Horizon’s expertise in translational genomics, and has led to the development of GENESIS™, the company’s proprietary genome-editing platform.
Entering the post-genomic era: Translating genetic information into personalized medicine
Horizon has used GENESIS™ to create over 1,000 products based around X-MAN™ (gene-X Mutant And Normal) isogenic cell lines, the world’s first source of genetically-defined and patient-relevant human cellular models. These disease models comprise two cell lines that are identical except for the targeted modification, allowing for the accurate study of normal vs. diseased biology, the identification or validation of novel drug targets, or the identification, development and prescription of targeted or ‘personalized’ medicines.
In addition to X-MAN™ cell lines, Horizon provides a range of products and services based on GENESIS™ and X-MAN™, with applications in: bio-pharmaceutical process optimization; clinical diagnostic development; drug discovery & development; and the provision of reference standards for genomics-based clinical research platforms. It is this latter offer that is the basis for Horizon Diagnostics.
Horizon aspires to provide science-driven research solutions that:
Paragraph explaining benefits of Biocair×